Clinical Significance of Serum Biomarkers: Vascular Endothelial Growth Factor-A and Chemokine (C-X-C motif) Ligand 13 in Egyptian Multiple Myeloma Patients
Multiple myeloma (MM) is a human B-cell neoplasia arising from malignant plasma cells. Vascular endothelial growth factor (VEGF) is among growth factors essential for angiogenesis in MM. However, chemokine (C-X-C motif) ligand 13 (CXCL13) allows the chemotaxis of mature B cells expressing its receptor CXCR5.CXCL13-CXCR5 interactions are involved in MM progression. This study aimed at investigating 2 serum biomarkers; VEGF-A and CXCL13 levels using enzyme linked immunosorbent assays (ELISA) in 48 Egyptian myeloma patients as well as correlation with different clinic-pathological features, survival and therapy response. VEGF-A and CXCL13 levels were significantly higher in MM cases in comparison to control group (P=0.04* and 0.01*, respectively). An indirect proportional relation between VEGF-A and CXCL13 levels in myeloma patients was found (r= -0.27, P=0.22). Alb/creat ratio change showed indirect proportional relation with VEGF-A (r= -0.446, P=0.043*). Patients obtained complete remission (CR)had insignificantly lower VEGF-A and higher CXCL13 levels compared to other patients, P=0.2 and 0.7, respectively. In conclusion, production of variety of growth factors and cytokines such as VEGF-A and CXCL13 was higher in MM patients. However, our experiment has to be done on larger sample size and extended period of follow up to validate the participation of the VEGF-A and CXCL13 in disease progression and clinical outcome.
2. Rajkumar SV. Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management. Am J Hematol2018;93:981-1114.
3. Kassem NM, Kassem HA, Ibrahim M, Zawam H, Hamada E. The clinical impact of hepatitis C virus infection in Egyptian multiple myeloma patients. J Egypt Natl Canc Inst2020;32:43.
4. Heher EC, Rennke HG, Laubach JP, Richardson PG. Kidney Disease and Multiple Myeloma. Clin J Am Soc Nephrol 2013;8:2007-17.
5. Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Fonseca R, et al. Expression of VEGF and its receptors by myeloma cells. Leukemia 2003;17:2025-31.
6. Rajkumar SV, Leong T, Roche PC, Fonseca R, Dispenzieri A, Lacy MQ,et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000;6:3111-6.
7. Podar K, Anderson KC. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 2005;105:1383-95.
8. Abd El Kader Y, Emera G, Safwat E, Kassem HA, Kassem NM.The KRAS StripAssay for detection of KRAS mutation in Egyptian patients with colorectal cancer (CRC): A pilot study. J Egypt Natl Canc Inst2013;25:37-41.
9. Lipp M, Bucher F, Parthasarathy A, Hos D, Onderka J, Cursiefen C, et al. Blockade of the VEGF isoforms in inflammatory corneal hemangiogenesis and lymphangiogenesis. Graefes Arch Clin Exp Ophthalmol2014;252:943-9.
10. Rao L, De Veirman K, Giannico D, Saltarella I, Desantis V, Frassanito MA, et al.Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin® protein MP0250: a preclinical study. Oncotarget2018;9:13366-81.
11. Todoerti K, Lisignoli G, Storti P, Agnelli L, Novara F, Manferdini C, et al. Distinct transcriptional profiles characterize bone microenvi¬ronment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease. Exp Hematol2010;38:141-53.
12. Adebayo OO, Young CD, Carey K, Dill CD, Nunez SK,Griffen TL,et al.Weighted Gene Co-expression Network Analysis of CXCL13, CXCR5, and associated genes in multiple myeloma. J Immunol 2019;202:194.36.
13. Ribatti D, Vacca A. New Insights in Anti-Angiogenesis in Multiple Myeloma. Int J Mol Sci 2018;19:2031.
14. Wright N, de Lera TL, Garcia-Moruja C, Lillo R, García-Sánchez F, Caruz A,et al. Transforming growth factor-betal down-regulates expression of chemokine stromal cell-derived factor-1: functional consequences in cell migration and adhesion. Blood 2003;102:1978-84.
15. Shen JK, Dong LH, Qi H, Zhang GS. Clinical significance of serum vascular endothelial growth factor and interleukin-6 in multiple myeloma. Zhong Nan Da Xue Xue Bao Yi Xue Ban2005;30:68-71.
16. Li X, Wei XZ, Liu JW, Geng CY,Chen WM.Clinical significance of serum vascular endothelial growth factor in patients with multiple myeloma. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2014;22:108-11.
17. Usnarska-Zubkiewicz L, Mazur G, Wróbel T, Poreba M, Kuliczkowski K.Expression of serum vascular endothelial growth factor correlates with clinical outcome in multiple myeloma. Pol Arch Med Wewn2003;110:719-24.
18. Iwasaki T, Hamano T, Ogata A, Hashimoto N, Kitano M, Kakishita E.Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma. Br J Haematol2002;116:796-802.
19. Beider K, Voevoda-Dimenshtein V, Zoabi A, Rosenberg E, Magen H, Ostrovsky O, et al. CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression. J Hematol Oncol 2022;15:144.
20. Zhang G, Miao F, Xu J, Wang R.Mesenchymal stem cells from bone marrow regulate invasion and drug resistance of multiple myeloma cells by secreting chemokine CXCL13. Bosn J Basic Med Sci 2020;20:209-17.
21. Bürkle A, Niedermeier M, Schmitt-Gräff A, Wierda WG, Keating MJ, Burger JA. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood 2007;110:3316-25.
|Issue||Vol 61 No 3 (2023)|
|Vascular endothelial growth factor-A (VEGF-A) Chemokine (C-X-C motif) ligand 13 (CXCL13) Multiple myeloma Clinical outcome|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|